Biosimilars – a Different type of aHUS Drug
Biosimilar drugs are having an increased presence in conversations about the aHUS therapeutic drug landscape. Here's why they're of interest.
2020 Atypical Drug Discovery Review, released by the aHUS Alliance
2020 overview of atypical HUS therapeutic drug development, by the aHUS Alliance
aHUS & COVID-19: WEBINAR 24 March 2020
Article No. 334 21 March 2020 The aHUS Alliance wishes to alert atypical HUS patients and family caregivers to the…
Global aHUS Registry: What’s it all About?
An article on FAQ regarding the aHUS global registry, including information gathered by atypical HUS patient advocates who represent the patient voice at the registry's Scientific Advisory Board meetings.
Where and what next?
Article No. 297 15 November 2019 There is a saying in “management theory” that in the development of a…
Small Molecule Factor D Inhibitors – Right for aHUS?
Out of more than 7000 rare diseases, only an estimated 5% have an approved treatment or therapy (Rare Disease Day, FAQs).…
Alexion holds Blood Drive for aHUS Day 2019
Alexion Pharmaceuticals holds corporate blood donation drive to mark aHUS Awareness Day, 24 Sept 2019.
aHUS Patients have a value beyond the balance sheet
It was little known, but Alexion decided years ago that it would reinvest 40% of any of its profits from the…
An open letter to Alexion for 2018
1 January 2018 Dear Alexion As you know aHUS is a life threatening and debilitating condition. You have the only treatment…